Humulin S (Soluble) (Insulin Human (Rdna))

Humulin S is indicated for the management of blood glucose in diabetes mellitus. It is used as part of a comprehensive diabetes treatment plan that may include diet, exercise, and other medications.

• Treatment of type 1 diabetes mellitus when basal insulin is combined with rapid‑acting insulin.
• Supplemental insulin for type 2 diabetes mellitus patients who require additional glucose control.
• Management of post‑prandial hyperglycemia.
• Use in insulin‑pump therapy where rapid‑acting insulin is required.
• Adjustment of insulin dose during illness, stress, or changes in physical activity.

• Humulin S contains insulin that binds to insulin receptors on muscle, adipose, and hepatic cells. Receptor activation triggers tyrosine kinase activity, leading to translocation of GLUT‑4 transporters to the cell surface, which enhances glucose uptake. In the liver, insulin suppresses gluconeogenesis and glycogenolysis, thereby reducing endogenous glucose production and lowering plasma glucose concentrations.

Humulin S may cause a range of adverse reactions, from mild to severe. Awareness of common and serious events helps patients and clinicians monitor therapy.

Common

• Hypoglycemia (low blood sugar)
• Injection site redness, swelling, or itching
• Lipodystrophy at injection sites
• Mild weight gain
• Transient headache

Serious

• Severe hypoglycemia with loss of consciousness
• Allergic reactions such as urticaria or angioedema
• Anaphylaxis
• Persistent edema or heart failure exacerbation
• Hypersensitivity leading to eosinophilia

When using Humulin S, several safety considerations should be observed to minimize risks.

• Monitor blood glucose regularly to detect hypoglycemia early.
• Adjust doses during pregnancy, illness, or changes in activity level.
• Use caution in patients with renal or hepatic impairment.
• Educate patients on proper injection technique to avoid lipodystrophy.
• Review cardiovascular status in patients with heart failure.
• Avoid use in individuals with known hypersensitivity to human insulin.

Humulin S can interact with various medications and substances, influencing its glucose‑lowering effect.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment.
• High‑dose beta‑blockers that may mask hypoglycemia symptoms.
• Alcohol excess, which can potentiate hypoglycemia.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk.
• Corticosteroids, which may raise blood glucose and require dose changes.
• Thyroid hormones, which can alter insulin sensitivity.
• Diuretics, especially thiazides, that may affect glucose control.